首页> 外文期刊>Annals of Clinical Microbiology and Antimicrobials >PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis
【24h】

PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis

机译:PknB仍然是结核分枝杆菌易感和MDR菌株药物开发的必不可少的目标

获取原文
           

摘要

Background The Mycobacterium tuberculosis ( M.tb ) protein kinase B (PknB) which is now proved to be essential for the growth and survival of M.tb , is a transmembrane protein with a potential to be a good drug target. However it is not known if this target remains conserved in otherwise resistant isolates from clinical origin. The present study describes the conservation analysis of sequences covering the inhibitor binding domain of PknB to assess if it remains conserved in susceptible and resistant clinical strains of mycobacteria picked from three different geographical areas of India. Methods A total of 116 isolates from North, South and West India were used in the study with a variable profile of their susceptibilities towards streptomycin, isoniazid, rifampicin, ethambutol and ofloxacin. Isolates were also spoligotyped in order to find if the conservation pattern of pknB gene remain consistent or differ with different spoligotypes. The impact of variation as found in the study was analyzed using Molecular dynamics simulations. Results The sequencing results with 115/116 isolates revealed the conserved nature of pknB sequences irrespective of their susceptibility status and spoligotypes. The only variation found was in one strains wherein pnkB sequence had G to A mutation at 664 position translating into a change of amino acid, Valine to Isoleucine. After analyzing the impact of this sequence variation using Molecular dynamics simulations, it was observed that the variation is causing no significant change in protein structure or the inhibitor binding. Conclusions Hence, the study endorses that PknB is an ideal target for drug development and there is no pre-existing or induced resistance with respect to the sequences involved in inhibitor binding. Also if the mutation that we are reporting for the first time is found again in subsequent work, it should be checked with phenotypic profile before drawing the conclusion that it would affect the activity in any way. Bioinformatics analysis in our study says that it has no significant effect on the binding and hence the activity of the protein.
机译:背景技术现已证明结核分枝杆菌(M.tb)蛋白激酶B(PknB)对M.tb的生长和存活至关重要,它是一种跨膜蛋白,有可能成为良好的药物靶标。然而,尚不知道该靶标是否在来自临床的其他抵抗力分离株中仍然保守。本研究描述了覆盖PknB抑制剂结合域的序列的保守性分析,以评估它在从印度三个不同地理区域中选出的易感和耐药的分枝杆菌临床菌株中是否仍然保守。方法本研究共使用来自印度北部,南部和西部的116种分离株,其对链霉素,异烟肼,利福平,乙胺丁醇和氧氟沙星的敏感性不同。为了确定pknB基因的保守模式是否与不同的spoligotype保持一致或不同,也对分离株进行了spoligotyped分析。使用分子动力学模拟分析了研究中发现的变化的影响。结果115/116分离株的测序结果揭示了pknB序列的保守性,无论其易感性状态和多态性。发现的唯一变异是在一种菌株中,其中pnkB序列在664位具有G到A突变,转化为氨基酸从缬氨酸到异亮氨酸的变化。在使用分子动力学模拟分析了该序列变异的影响后,观察到该变异不会引起蛋白质结构或抑制剂结合的显着变化。结论因此,该研究支持PknB是药物开发的理想靶标,并且与抑制剂结合相关的序列没有预先存在的或诱导的耐药性。同样,如果在随后的工作中再次发现我们首次报告的突变,则应在确定可能以任何方式影响该活性的结论之前,通过表型分析检查该突变。我们研究中的生物信息学分析表明,它对蛋白质的结合并因此对其活性没有明显影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号